WO2000012682A1 - Cellules souches embryonnaires de primates a genes d'histocompatibilite compatibles - Google Patents

Cellules souches embryonnaires de primates a genes d'histocompatibilite compatibles Download PDF

Info

Publication number
WO2000012682A1
WO2000012682A1 PCT/US1999/009784 US9909784W WO0012682A1 WO 2000012682 A1 WO2000012682 A1 WO 2000012682A1 US 9909784 W US9909784 W US 9909784W WO 0012682 A1 WO0012682 A1 WO 0012682A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
donor
primate
embryonic stem
Prior art date
Application number
PCT/US1999/009784
Other languages
English (en)
Inventor
James A. Thomson
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Priority to AU38814/99A priority Critical patent/AU3881499A/en
Priority to CA002342205A priority patent/CA2342205A1/fr
Priority to EP99921665A priority patent/EP1117764A1/fr
Priority to IL14169999A priority patent/IL141699A0/xx
Priority to JP2000567669A priority patent/JP2002523084A/ja
Publication of WO2000012682A1 publication Critical patent/WO2000012682A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Definitions

  • the present invention relates to production of primate embryonic stem (ES) cells that are MHC-matched to a specific donor individual. More particularly, it relates to ES cells that are designed to be genetically identical for all nuclear genes to the donor.
  • ES primate embryonic stem
  • transplantation therapies Such cells derived from undifferentiated primate ES cells were in part developed to provide source material for transplantation therapies.
  • ES cell-based transplantation therapies a potential problem with ES cell-based transplantation therapies is the possibility of immune rejection of the transplanted cells. While there are a number of drugs that suppress immune rejection responses, they typically have side effects and significant cost. It is preferable to provide transplantation therapies which minimize or eliminate the need for such drugs.
  • stem cells e.g. capable of prolonged undifferentiated proliferation, capable of differentiation of the three embryonic germ layers.
  • MHC- compatible I mean that the cell has a major histocompatibility complex that matches that of the selected donor.
  • the invention provides a purified preparation of primate (preferably human) embryonic stem cells which (i) is capable of proliferation in an in vitro culture, (ii) maintains the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues in the culture, (iii) is inhibited from differentiation when cultured on a fibroblast feeder layer, and (iv) has a major histocompatibility complex from a foreign source (e.g. one derived from a donor) .
  • a foreign source e.g. one derived from a donor
  • the cell is genetically identical with respect to all nuclear genes to a specified nuclear donor .
  • ES cell are viable with changes in the status of imprinted genes.
  • the derivation of ES cells by the transfer of differentiated cell nuclei to an enucleated oocytes should allow the formation of histocompatible ES cells even when the nucleus is from a cell that would not allow the cloning of an intact adult primate.
  • a method for creating the aforesaid cells wherein the cells are derived by transplantation of cell nucleus from a differentiated cell of the donor to an enucleated primate (preferably human) oocyte.
  • an enucleated primate preferably human
  • ES cells By reprogramming the nucleus of a differentiated cell from a specific individual to an ES cell nuclear state, it is possible to make ES cells that are MHC- matched to the specific individual. So, for example, one can take a skin fibroblast or other cell from a patient with juvenile onset diabetes, reprogram the differentiated nucleus by transfer to an enucleated oocyte, culture the nuclear transfer product to the blastocyst stage, derive undifferentiated ES cells from the inner cell mass, differentiate the ES cells to pancreatic ⁇ -cells, and use those ⁇ -cells for transplantation therapy to treat the diabetes in the same way that whole pancreas transplants are currently used for this purpose (albeit without the need for immunosuppressive drugs) .
  • the reprogrammed cells would be genetically matched for all nuclear genes of the nuclear donor including genes of the major histocompatibility complex (MHO . Immune rejection of these cells by the individual that donated the nucleus is therefore much less likely.
  • the MHC-matched ES cells can be formed by fusion between differentiated cell karyoplasts from a donor and primate ES or primate embryonal carcinoma (EC) cell cytoplasts.
  • Human embryonal carcinoma (EC) cells are the stem cells of teratocarcinomas .
  • EC cells are essentially the malignant equivalent to ES cells, and some human EC cell lines maintain the potential to form all three embryonic germ layers. Because human EC cells are highly aneuploid (lack a normal complement of chromosomes) , they have a significantly more restricted developmental potential than ES cells.
  • the objects of the present invention therefore include providing :
  • Primate oocytes can then be activated by known osmotic (J. Levron et al . , 3 Zygote 157-161 (1995)), electrical (V. Marshall et al . , 9 Abstr. Serv. 98 J. Reprod. Fertil. (1992)), chemical (6-DMAP/ionomycin, SR 2+ or cyclohexamide - G. Wu, 55 Biol. Reprod. 260-270 (1996); L. Meng et al . , 57 Biol. Reprod. 454-459 (1997); T. Wakayama et al. , 394 Nature 369 (1998)), or biological (injection of sperm factor - H. Wu e_t al .
  • Fibroblasts or other donor cell types can be prepared from fetal or postnatal tissues (e.g. skin biopsy) by mechanical disruption followed by trypsinization and cultured in DMEM-10% Fetal Calf Serum (FCS) . See generally E. Robertson, Teratocarcinoma And Embryonic Stem Cells : A Practical Approach, IRL Press, Washington, D.C. 71-112 (1987) .
  • Mil oocytes are proposed to be incubated in transfer medium containing the cytoskeletal inhibitor cytochalasin B (7.5 ⁇ g/ml) . See generally L. Meng et al . , 57 Biol. Reprod. 454-459 (1997) .
  • Enucleation is then proposed to be accomplished with a beveled micropipette (J. McGrath et al . , 228 Exper. Zoo . 355-362 (1983) and J. McGrath et al. 220 Science 1300-1302 (1983) , and enucleation confirmed by staining of the removed karyoplast with the dye Hoechst 33342 (3 ⁇ g/ml) and direct observation under epifluorescence . See generally S. Stice et al . , 54 Biol. Reprod. 100-110 (1996) . A single donor cell is then proposed to be selected with the micropipette and injected under the zona pellucida. Fusion
  • Fusion of the donor cell and oocyte cytoplast are proposed to be accomplished by viral (J. McGrath et al., 228 Exper. Zoo . 355-362 (1983) and J. McGrath et al. 220 Science 1300-1302 (1983), chemical (M. Sims et al., 91 P.N.A.S. USA 6143-6173 (1994), or electrical methods (L. Meng et al., 57 Biol. Reprod. 454-459 (1997).
  • nuclei are proposed to be injected directly into the cytoplasm using techniques analogous to the injection techniques described in T. Wakayama et al . , 394 Nature 369 (1998)
  • the nuclear transfer products are proposed to be cultured to the blastocyst stage in standard medium used in human IVF clinics, such as S1/S2 or G1.2/G2.2 medium (Scandinavian IVF Science AB, Gothenburg, Sweden) .
  • the inner cell mass of the resulting blastocyst should then be removed by immunosurgery (D. Solter et al . , 72 P.N.A.S. USA 5099-5102 (1975)), and cultured on mitotically inactivated fibroblasts. After approximately 9-15 days, the resulting mass of cells should then be dissociated, replated on fibroblasts, and ES cells selected by their characteristic morphology and expanded. See J. Thomson et al . , 38 Curr. Top.
  • ES cells or preferably ES cell cytoplasts
  • rhesus ES cells XX karyotype
  • primary embryonic fibroblasts an XY karyotype
  • the rhesus ES cells and fibroblasts containing these markers are then proposed to be fused by electrofusion or by other chemical fusion methods. See generally N. Duzgunes 220 Methods Enzymol . (1993), and heterokaryons selected for hygromycin/neomycin resistance.
  • the resulting clones are proposed to be expanded, karyotyped, injected into SCID mice, and analyzed for contributions to derivatives of all three embryonic germ layers. This will determine whether undifferentiated ES cells can reprogram differentiated nuclei using this technique to create tetraploid heterokaryons.
  • rhesus ES cell cytoplasts and neomycin resistant fibroblast karyoplasts be prepared and fused by similar methods. See generally N. Duzgunes, 220 Methods Enzymol. (1993) . The fusion products will be plated on neomycin resistant primary fibroblasts under
  • ES cells can be characterized by their ability to differentiate to derivatives of all three embryonic germ layers, endoderm, mesoderm, and ectoderm even after prolonged culture. This is demonstrated either by letting the cells over-grow and pile up in culture, when spontaneous differentiation occurs, or by injecting into immunocompromised mice, where teratomas form with cells representing all three germ layers. D. Application
  • a cell e.g. a skin fibroblast or other cell
  • a disease e.g. juvenile onset diabetes
  • the invention is designed to provide precursors for developing transplantable cells. These cells are intended to be useful for therapeutic and other purposes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

L'invention se rapporte à des procédés de production de cellules souches embryonnaires (ES) de primates qui sont appariées par LMH à un sujet donneur spécifique. Selon un des aspects de l'invention, on effectue une transplantation de noyaux cellulaires d'un primate donneur sur un ovocyte de primate énucléé. La culture du produit de transfert nucléaire résultant jusqu'à l'étape des blastocystes et l'isolement subséquent des cellules ES de primate à partir de la masse cellulaire interne est conçue pour permettre la production de cellules ES qui sont génétiquement identiques, pour tous les gènes nucléaires, au donneur du noyau d'origine. Des cellules différenciées dérivées de ces cellules ES de primates ont moins tendance à être rejetées par le système immunitaire du donneur lorsqu'elles sont utilisées à des fins thérapeutiques du type transplantation.
PCT/US1999/009784 1998-09-01 1999-05-05 Cellules souches embryonnaires de primates a genes d'histocompatibilite compatibles WO2000012682A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU38814/99A AU3881499A (en) 1998-09-01 1999-05-05 Primate embryonic stem cells with compatible histocompatibility genes
CA002342205A CA2342205A1 (fr) 1998-09-01 1999-05-05 Cellules souches embryonnaires de primates a genes d'histocompatibilite compatibles
EP99921665A EP1117764A1 (fr) 1998-09-01 1999-05-05 Cellules souches embryonnaires de primates a genes d'histocompatibilite compatibles
IL14169999A IL141699A0 (en) 1998-09-01 1999-05-05 Primate embryonic stem cells with compatible histocompatibility genes
JP2000567669A JP2002523084A (ja) 1998-09-01 1999-05-05 適合性組織適合遺伝子を有する霊長類の胚幹細胞

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9871298P 1998-09-01 1998-09-01
US60/098,712 1998-09-01

Publications (1)

Publication Number Publication Date
WO2000012682A1 true WO2000012682A1 (fr) 2000-03-09

Family

ID=22270566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009784 WO2000012682A1 (fr) 1998-09-01 1999-05-05 Cellules souches embryonnaires de primates a genes d'histocompatibilite compatibles

Country Status (6)

Country Link
EP (1) EP1117764A1 (fr)
JP (1) JP2002523084A (fr)
AU (1) AU3881499A (fr)
CA (1) CA2342205A1 (fr)
IL (1) IL141699A0 (fr)
WO (1) WO2000012682A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044343A2 (fr) * 2000-11-22 2002-06-06 Geron Corporation Tolerisation d'allogreffes de cellules souches totipotentes
WO2002046401A1 (fr) * 2000-12-04 2002-06-13 Max-Delbrück-Centrum für Molekulare Medizin Utilisation de cellules derivees de cellules souches embryonnaires pour augmenter la tolerance aux transplantations et pour regenerer un tissu altere
WO2002057429A2 (fr) * 2001-01-02 2002-07-25 Stemron, Inc. Procede permettant de produire une population de cellules souches homozygotes dont l'immunotype et/ou le genotype sont preselectionnes, cellules convenant a une transplantation derivee dudit procede et materiaux et procedes utilisant lesdites cellules
WO2004038012A1 (fr) * 2002-10-25 2004-05-06 Hunan Hui-Lin Life Technology Co. Ltd Couche de cellules nourricieres pour la culture in vitro de cellules souches embryonnaires humaines et methode de culture de cellules souches embryonnaires
US6759244B2 (en) 2001-11-08 2004-07-06 Art Institute Of New York And New Jersey, Inc. Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos
EP1437404A1 (fr) * 2001-09-21 2004-07-14 ReproCELL Inc. Cellules souches multifonctionnelles adaptees et utilisation de ces dernieres
WO2005013679A1 (fr) * 2003-08-07 2005-02-17 Ivan De Weber Méthode de clonage reproductif et non reproductif
GB2412379A (en) * 2001-12-07 2005-09-28 Geron Corp Embryonic stem cells to induce immune tolerance and improve allograft acceptance
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7462448B2 (en) 2002-08-02 2008-12-09 Stratatech Corporation Species specific DNA detection
US7799324B2 (en) 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63248385A (ja) * 1987-04-03 1988-10-14 Kingo Yoshida 老化体同一若細胞移植及び老化防止若遺伝子注入による若返り長命法
WO1995003398A1 (fr) * 1993-07-23 1995-02-02 Monash University Enucleation des ovocytes
WO1996022362A1 (fr) * 1995-01-20 1996-07-25 Wisconsin Alumni Research Foundation Cellules souches embryonnaires de primates
WO1998007841A1 (fr) * 1996-08-19 1998-02-26 University Of Massachusetts Lignees de cellules embryonnaires ou de type souche produites par transplantation nucleaire croisee d'especes
WO1998030683A2 (fr) * 1997-01-10 1998-07-16 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts Transfert nucleaire au moyen de cellules donneuses foetales et adultes differentiees
DE19709549A1 (de) * 1997-03-07 1998-09-24 Eberhard Prof Dr Born Regeneration von Gewebe bei Mammalia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63248385A (ja) * 1987-04-03 1988-10-14 Kingo Yoshida 老化体同一若細胞移植及び老化防止若遺伝子注入による若返り長命法
WO1995003398A1 (fr) * 1993-07-23 1995-02-02 Monash University Enucleation des ovocytes
WO1996022362A1 (fr) * 1995-01-20 1996-07-25 Wisconsin Alumni Research Foundation Cellules souches embryonnaires de primates
WO1998007841A1 (fr) * 1996-08-19 1998-02-26 University Of Massachusetts Lignees de cellules embryonnaires ou de type souche produites par transplantation nucleaire croisee d'especes
WO1998030683A2 (fr) * 1997-01-10 1998-07-16 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts Transfert nucleaire au moyen de cellules donneuses foetales et adultes differentiees
DE19709549A1 (de) * 1997-03-07 1998-09-24 Eberhard Prof Dr Born Regeneration von Gewebe bei Mammalia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 8847, Derwent World Patents Index; Class D16, AN 88-334664, XP002114590 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7659118B2 (en) 1999-08-05 2010-02-09 Abt Holding Company Multipotent adult stem cells
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US10226485B2 (en) 1999-08-05 2019-03-12 Abt Holding Company Multipotent adult stem cells and methods for isolation
GB2386125A (en) * 2000-11-22 2003-09-10 Geron Corp Tolerizing allografts of pluripotent stem cells
WO2002044343A3 (fr) * 2000-11-22 2003-01-16 Geron Corp Tolerisation d'allogreffes de cellules souches totipotentes
GB2386125B (en) * 2000-11-22 2005-02-23 Geron Corp Tolerizing allografts of pluripotent stem cells
WO2002044343A2 (fr) * 2000-11-22 2002-06-06 Geron Corporation Tolerisation d'allogreffes de cellules souches totipotentes
EP1757681A1 (fr) * 2000-11-22 2007-02-28 Geron Corporation Tolérisation d'allogreffes de cellules souches totipotentes
WO2002046401A1 (fr) * 2000-12-04 2002-06-13 Max-Delbrück-Centrum für Molekulare Medizin Utilisation de cellules derivees de cellules souches embryonnaires pour augmenter la tolerance aux transplantations et pour regenerer un tissu altere
WO2002057429A3 (fr) * 2001-01-02 2003-10-09 Stemron Inc Procede permettant de produire une population de cellules souches homozygotes dont l'immunotype et/ou le genotype sont preselectionnes, cellules convenant a une transplantation derivee dudit procede et materiaux et procedes utilisant lesdites cellules
US7030292B2 (en) 2001-01-02 2006-04-18 Stemron, Inc. Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
WO2002057429A2 (fr) * 2001-01-02 2002-07-25 Stemron, Inc. Procede permettant de produire une population de cellules souches homozygotes dont l'immunotype et/ou le genotype sont preselectionnes, cellules convenant a une transplantation derivee dudit procede et materiaux et procedes utilisant lesdites cellules
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
EP1437404A1 (fr) * 2001-09-21 2004-07-14 ReproCELL Inc. Cellules souches multifonctionnelles adaptees et utilisation de ces dernieres
EP1437404A4 (fr) * 2001-09-21 2005-10-26 Reprocell Inc Cellules souches multifonctionnelles adaptees et utilisation de ces dernieres
US6759244B2 (en) 2001-11-08 2004-07-06 Art Institute Of New York And New Jersey, Inc. Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos
GB2412379B (en) * 2001-12-07 2006-03-29 Geron Corp Hematopoietic cells from human embryonic stem cells
US7799324B2 (en) 2001-12-07 2010-09-21 Geron Corporation Using undifferentiated embryonic stem cells to control the immune system
GB2412379A (en) * 2001-12-07 2005-09-28 Geron Corp Embryonic stem cells to induce immune tolerance and improve allograft acceptance
CN102008503A (zh) * 2001-12-07 2011-04-13 杰龙公司 人胚胎干细胞衍生的造血细胞
CN102008503B (zh) * 2001-12-07 2018-10-09 阿斯特利亚斯生物治疗股份公司 人胚胎干细胞衍生的造血细胞
US7462448B2 (en) 2002-08-02 2008-12-09 Stratatech Corporation Species specific DNA detection
US7888496B2 (en) 2002-08-02 2011-02-15 Stratatech Corporation Kit for species specific DNA detection
WO2004038012A1 (fr) * 2002-10-25 2004-05-06 Hunan Hui-Lin Life Technology Co. Ltd Couche de cellules nourricieres pour la culture in vitro de cellules souches embryonnaires humaines et methode de culture de cellules souches embryonnaires
WO2005013679A1 (fr) * 2003-08-07 2005-02-17 Ivan De Weber Méthode de clonage reproductif et non reproductif
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells

Also Published As

Publication number Publication date
AU3881499A (en) 2000-03-21
IL141699A0 (en) 2002-03-10
JP2002523084A (ja) 2002-07-30
CA2342205A1 (fr) 2000-03-09
EP1117764A1 (fr) 2001-07-25

Similar Documents

Publication Publication Date Title
US5945577A (en) Cloning using donor nuclei from proliferating somatic cells
US10047340B2 (en) Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
AU740709B2 (en) Embryonic or stem-like cell lines produced by cross species nuclear transplanta tion
US20130102073A1 (en) Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
CA2387506C (fr) Production gynogenetique ou androgenetique de cellules et de lignees cellulaires pluripotentes et leur utilisation dans la production de cellules et de tissus differencies
EP1117764A1 (fr) Cellules souches embryonnaires de primates a genes d'histocompatibilite compatibles
EP1149898A2 (fr) Cellules d'ongules, souches d'embryons utilisees comme donneuses de noyaux et procedes de transfert de noyaux pour la production d'animaux chimeriques et transgeniques
NZ502129A (en) Cloning using donor nuclei from non-serum starved, differentiated cells
EP1198169B1 (fr) Processus de reprogrammation cellulaire par production d'un heterocaryon
EP1513928B1 (fr) Banque de cellules souches destinees a la production de cellules pour transplantation possedant des antigenes hla correspondant a ceux des receveurs de transplant, et procedes de constitution et d'utilisation d'une telle banque de cellules souches
US7527974B2 (en) Embryonic stem cells derived from human somatic cell—rabbit oocyte NT units
AU2563600A (en) Pluripotential cells-2
MXPA01002174A (en) Primate embryonic stem cells with compatible histocompatibility genes
Galat et al. Effect of donor cell age on the efficiency of nuclear transfer in rabbits
Hwang et al. Mobilis in Mobile–Human Embryonic Stem Cells and Other Sources for Cell Therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2342205

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2342205

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002174

Country of ref document: MX

Ref document number: 141699

Country of ref document: IL

Ref document number: 510235

Country of ref document: NZ

Ref document number: 09786174

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 567669

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999921665

Country of ref document: EP

Ref document number: 38814/99

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999921665

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999921665

Country of ref document: EP